Loading
Vistin Pharma ASA Stock: price and insider trades · Norway
No insider purchase over the last 90 days. The latest was filed 16 Mar 2021.
Vistin Pharma ASA: what insiders have been doing
Vistin Pharma ASA, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to Oslo Børs. In the past year (18 October 2025 to 18 October 2026), 1 filing came from 1 insider.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
For context, the typical company on the same exchange (median of 258 companies) published 4 filings over the same period, against 1 filing here. The full history, which starts in 2021, counts 1 purchase against 7 sales.
There has been no open-market purchase by an insider of Vistin Pharma ASA for at least a year.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by Oslo Børs. They describe what insiders did and are not a recommendation.
Insider Decl.
18
Thresholds
n/a
Buy Volume
n/a
1 ops. · all time
Sell Volume
€12M
7 ops. · all time
Who traded when
BuySaleIntertrade Shipping AS1 sale
Since the insiders bought
- Unknown insider (VISTN)-35.9%Entry NOK 27.30 · Close at T+365 NOK 17.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 869 of 24,158 companies
80.9
score / 100
Value76
Quality85
FCF yld6.8%
Earn yld8.3%
EV/EBITDA7.4x
ROE22%
Gross mgn51%
Net mgn17%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
NOK 20.20
Analyst consensus
Income statement
RevenueNOK 452.3M
Gross profitNOK 232M51% margin
EBITDANOK 120.3M27% margin
Net incomeNOK 74.8M16.6% margin
Valuation
PER (trailing)12.0x
P/Book2.7x
Beta0.61
Balance sheet & cash
Market capNOK 895.8M
Total debtNOK 619k
Free Cash FlowNOK 61.4M
Debt / Equity0%
Profitability & ownership
ROE21.9%
ROA12.8%
% insiders58.9%
% institutions13.7%
Last declaration on 20 February 2026
Declarations18 total
30 shares@ NOK 21.100.3% of flowShareXOSLOSLO:666416
1,234,280 shares@ NOK 22.50100.0% of flowShareXOSLOSLO:645424
527,960 shares@ NOK 22.0247100.0% of flowShareXOSLOSLO:614472
@ €1.9837ShareXOSLOSLO:594694
15 shares@ NOK 24.010.2% of flowShareXOSLOSLO:592067
3,519,733 shares@ NOK 19.5081.3% of flowShareXOSLOSLO:545546
784,280 shares@ NOK 21.1018.7% of flowShareXOSLOSLO:542310
14,182 shares@ NOK 24.00100.0% of flowShareXOSLOSLO:533509
1,500,000 shares0.0% of flowShareXOSLOSLO:527782
Canonical exit: 14 Jun 2021 (T+90)
10,000 shares@ NOK 17.3099.5% of flowShareXOSLOSLO:522056
18 of 18 declarations
About Vistin Pharma ASA
Vistin Pharma ASA is a Norwegian company focused on the development and production of pharmaceuticals for the treatment of metabolic diseases. It is listed on the Oslo Stock Exchange under the symbol XOSL.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
